________________________________________________________
____Explicit____
332..336
2,1,1
#### Text ####
also
##############
#### Features ####
Wr, Comm, Null, Null
also, Expansion.Conjunction
____Arg1____
223..324
1
#### Text ####
The move is sure to heighten concerns about increased Japanese investment in U.S. biotechnology firms
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
326..331;337..482
2,0;2,1,0;2,1,2;2,2
#### Text ####
It is likely to bolster fears that the Japanese will use their foothold in U.S. biotechnology concerns to gain certain trade and competitive advantages
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
746..750
4,1,1
#### Text ####
then
##############
#### Features ####
Wr, Comm, Null, Null
then, Temporal.Asynchronous.Precedence
____Sup1____
548..598
3,0,2,1,1,1,1,2
#### Text ####
which is a new technology used in diagnostic tests
##############
____Arg1____
486..546;600..730
3,0,0;3,0,1;3,0,2,0;3,0,2,1,0;3,0,2,1,1,0;3,0,2,1,1,1,0;3,0,2,1,1,1,1,0;3,0,2,1,1,1,1,1;3,0,3;3,1;3,2;3,3
#### Text ####
Gen-Probe, an industry leader in the field of genetic probes last year signed an agreement for Chugai to exclusively market its diagnostic products in Japan for infectious diseases and cancer
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
732..745;751..808
4,0;4,1,0;4,1,2;4,2
#### Text ####
Chugai agreed to fund certain associated research and development costs
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
857..860
5,2
#### Text ####
and
##############
#### Features ####
Wr, Comm, Null, Null
and, Expansion.Conjunction
____Arg1____
812..855
5,0
#### Text ####
That arrangement apparently has worked well
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
861..1091
5,3
#### Text ####
Thomas A. Bologna, president and chief executive officer of Gen-Probe, founded in 1983, said the sale of the company means "we will be able to concentrate on running the business rather than always looking for sources of financing
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
1094
6
____Arg1____
812..1091
5
#### Text ####
That arrangement apparently has worked well, and Thomas A. Bologna, president and chief executive officer of Gen-Probe, founded in 1983, said the sale of the company means "we will be able to concentrate on running the business rather than always looking for sources of financing
##############
____Arg2____
1094..1208
6
#### Text ####
Chugai agreed to pay $6.25 a share for Gen-Probe's 17.6 million common shares outstanding on a fully diluted basis
##############
________________________________________________________
________________________________________________________
____Explicit____
1319..1326
8,0,0
#### Text ####
Because
##############
#### Features ####
Wr, Comm, Null, Null
because, Contingency.Cause.Reason
____Arg1____
1441..1604
8,1;8,2;8,3
#### Text ####
the sale is sure to increase concerns that Japanese companies will buy American know-how and use it to obtain the upper hand in biotechnology trade and competition
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1327..1440
8,0,1
#### Text ####
the U.S. leads in most areas of biotechnology -- largely because of research investment by the U.S. government --
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1760
10
#### Features ####
Ot, Comm, Null, Null
1751..1759
10,0;10,1,0;10,2
#### Text ####
He added
##############
as, Contingency.Cause.Reason
____Arg1____
1609..1672
9,1
#### Text ####
The biotechnology firms may be setting up their own competitors
##############
#### Features ####
Ot, Comm, Null, Null
1675..1749
9,0;9,2;9,3;9,4;9,5;9,6
#### Text ####
said Richard Godown, president of the Industrial Biotechnology Association
##############
____Arg2____
1760..1855
10,1,1
#### Text ####
that until now the Japanese have only acquired equity positions in U.S. biotechnology companies
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1858
11
#### Features ####
Ot, Comm, Null, Null
1908..1915
11,0;11,2;11,3;11,4;11,5;11,6
#### Text ####
he said
##############
in other words, Expansion.Restatement.Equivalence
____Arg1____
1760..1855
10,1,1
#### Text ####
that until now the Japanese have only acquired equity positions in U.S. biotechnology companies
##############
#### Features ####
Ot, Comm, Null, Null
1751..1759
10,0;10,1,0;10,2
#### Text ####
He added
##############
____Arg2____
1858..1905
11,1
#### Text ####
They are piggybacking onto developed technology
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1917
12
#### Features ####
Wr, Comm, Null, Null
specifically, Expansion.Restatement.Specification
____Arg1____
1858..1905
11,1
#### Text ####
They are piggybacking onto developed technology
##############
#### Features ####
Ot, Comm, Null, Null
1908..1915
11,0;11,2;11,3;11,4;11,5;11,6
#### Text ####
he said
##############
____Arg2____
1917..2041
12
#### Text ####
During the past five years, Japanese concerns have invested in several of the U.S.'s 431 independent biotechnology companies
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
2043
13
#### Features ####
Wr, Comm, Null, Null
specifically, Expansion.Instantiation
____Arg1____
1917..2041
12
#### Text ####
During the past five years, Japanese concerns have invested in several of the U.S.'s 431 independent biotechnology companies
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2043..2268
13
#### Text ####
Chugai has been one of the most active Japanese players in U.S. biotechnology companies; it has an equity investment in Genetics Institute Inc., Cambridge, Mass., and a joint-venture agreement with Upjohn Co., Kalamazoo, Mich
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
2132
13
#### Features ####
Wr, Comm, Null, Null
for instance, Expansion.Instantiation
____Arg1____
2043..2130
13,0
#### Text ####
Chugai has been one of the most active Japanese players in U.S. biotechnology companies
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2132..2268
13,2
#### Text ####
it has an equity investment in Genetics Institute Inc., Cambridge, Mass., and a joint-venture agreement with Upjohn Co., Kalamazoo, Mich
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
2418
15
#### Features ####
Ot, Comm, Null, Null
2493..2500
15,0;15,2;15,3;15,4;15,5,0;15,5,1;15,5,2;15,6
#### Text ####
he said
##############
indeed, Expansion.Restatement.Generalization
____Arg1____
2325..2415
14,2,1,1
#### Text ####
that it wants 10% to 11% of its gross national product to come from biotechnology products
##############
#### Features ####
Ot, Comm, Null, Null
2272..2295;2314..2324
14,0;14,2,0;14,2,1,0;14,3
#### Text ####
The Japanese government has stated
##############
____Arg2____
2418..2490
15,1
#### Text ####
It is becoming more of a horse race every day between the U.S. and Japan
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
3285
19
____Arg1____
3103..3282
18
#### Text ####
Osamu Nagayama, deputy president of Chugai, which spends about 15% of its sales on research and development, was unable to pinpoint how much money Chugai would pump into Gen-Probe
##############
____Arg2____
3285..3423
19
#### Text ####
We think Gen-Probe has technology important to people's health," he said, adding: "We think it is important for us to have such technology
##############
________________________________________________________
________________________________________________________
____Implicit____
3456
20
#### Features ####
Wr, Comm, Null, Null
in addition, Expansion.Conjunction
____Arg1____
3377..3423
19,5,3,1,3,1,1
#### Text ####
it is important for us to have such technology
##############
#### Features ####
Ot, PAtt, Null, Null
3368..3376
19,5,3,1,3,0;19,5,3,1,3,1,0
#### Text ####
We think
##############
____Arg2____
3456..3606
20,1,1
#### Text ####
that both companies would gain technological knowledge through the sale of Gen-Probe, which will expand "significantly" as a result of the acquisition
##############
#### Features ####
Ot, Comm, Null, Null
3426..3455
20,0;20,1,0;20,2
#### Text ####
He and Mr. Bologna emphasized
##############
________________________________________________________
________________________________________________________
____Implicit____
3684
22
#### Features ####
Wr, Comm, Null, Null
by comparison, Comparison.Contrast.Juxtaposition
____Arg1____
3610..3682
21
#### Text ####
In 1988, Chugai had net income of $60 million on revenue of $991 million
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3684..3750
22
#### Text ####
GenProbe had a net loss of $9.5 million on revenue of $5.8 million
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
3752
23
#### Features ####
Wr, Comm, Null, Null
however, Comparison.Concession.Contra-expectation
____Arg1____
3684..3750
22
#### Text ####
GenProbe had a net loss of $9.5 million on revenue of $5.8 million
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3752..3951
23
#### Text ####
Recently, Gen-Probe received a broad U.S. patent for a technology that helps detect, identify and quantify non-viral organisms through the targeting of a form of genetic material called ribosomal RNA
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
4124..4128
25,0,1
#### Text ####
also
##############
#### Features ####
Ot, Comm, Null, Null
4202..4218
25,1;25,2;25,3;25,4
#### Text ####
Mr. Bologna said
##############
also, Expansion.Conjunction
____Arg1____
3992..4113
24,3,1
#### Text ####
that the sale will facilitate Gen-Probe's marketing of a diagnostic test for acquired immune deficiency syndrome, or AIDS
##############
#### Features ####
Ot, Comm, Null, Null
3955..3991
24,0;24,1;24,2;24,3,0;24,4
#### Text ####
Among other things, Mr. Bologna said
##############
____Arg2____
4117..4123;4129..4200
25,0,0;25,0,2
#### Text ####
Chugai will help Gen-Probe with its regulatory and marketing expertise in Asia
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
4220
26
____Arg1____
4117..4218
25
#### Text ####
Chugai also will help Gen-Probe with its regulatory and marketing expertise in Asia, Mr. Bologna said
##############
____Arg2____
4220..4310
26
#### Text ####
The tender offer for Gen-Probe's shares is expected to begin next Monday, the company said
##############
________________________________________________________
